U.S. markets close in 13 minutes
  • S&P 500

    4,358.93
    -84.18 (-1.89%)
     
  • Dow 30

    34,335.71
    -533.66 (-1.53%)
     
  • Nasdaq

    14,570.18
    -399.79 (-2.67%)
     
  • Russell 2000

    2,237.20
    -43.80 (-1.92%)
     
  • Crude Oil

    74.79
    -0.66 (-0.87%)
     
  • Gold

    1,733.50
    -18.50 (-1.06%)
     
  • Silver

    22.47
    -0.23 (-1.01%)
     
  • EUR/USD

    1.1682
    -0.0019 (-0.16%)
     
  • 10-Yr Bond

    1.5340
    +0.0500 (+3.37%)
     
  • GBP/USD

    1.3532
    -0.0172 (-1.26%)
     
  • USD/JPY

    111.5240
    +0.5460 (+0.49%)
     
  • BTC-USD

    41,608.70
    -1,566.46 (-3.63%)
     
  • CMC Crypto 200

    1,025.68
    -31.47 (-2.98%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

Abbott beats profit estimates as medical device sales rebound

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
Boxes of Abbott's heart stents are pictured inside a store at a hospital in New Delhi
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) -Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.

The strong results saw the company join rival Quest Diagnostics in signaling a recovery in their mainstay businesses, after a year in which they had to depend on coronavirus testing to bring in sales.

Abbott said its second-quarter sales, excluding COVID testing, rose more than 11% on an organic basis from the pre-pandemic levels recorded in 2019.

Its worldwide diagnostics revenue, excluding coronavirus testing, increased 42.5% from a year earlier, while medical devices sales rose 51.3% on the back of growth in its heart devices business.

But the rise in vaccinations pulled down its COVID-19 testing-related sales to $1.3 billion, from $2.2 billion in the previous quarter.

The company reiterated its 2021 adjusted earnings forecast of $4.30 to $4.50 per share from continuing operations.

The robust quarterly performance is a positive sign for the continued recovery in the medical device industry, J.P.Morgan analyst Robbie Marcus said in a note.

Marcus added that the company's outlook "leaves room at both ends to continue to adjust to the evolving COVID landscape."

Excluding items, Abbott earned $1.17 per share, beating analysts' estimates of $1.02 per share, according to Refinitiv IBES data.

(Reporting by Amruta Khandekar and Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber and Aditya Soni)